膳食谷氨酰胺补充剂治疗感染后肠易激综合征的随机安慰剂对照试验
本研究为随机双盲安慰剂对照8周试验,评估口服谷氨酰胺治疗肠道感染后出现肠道高通透性的腹泻型肠易激综合征(IBS-D)患者的疗效与安全性。谷氨酰胺组主要终点达标率79.6%,安慰剂组5.8%,差异达14倍;所有次要终点均值也均降低,不良事件少且两组相似,无严重不良事件。作者结论认为口服谷氨酰胺可显著且安全地改善IBS相关终点,但需大型随机临床试验验证。
要点
- 谷氨酰胺组主要终点(IBS-SS评分降低≥50分)达标43例(79.6%),安慰剂组3例(5.8%),差异达14倍。
- 8周时谷氨酰胺组IBS-SS评分301 vs 安慰剂组181,p<0.0001;每日排便频率5.4 vs 2.9±1.0,p<0.0001。
- 谷氨酰胺组Bristol粪便量表6.5 vs 安慰剂组3.9,p<0.0001;肠道通透性0.11 vs 0.05,p<0.0001;不良事件少且两组相似。
核心结论
- 在肠道感染后出现肠道高通透性的IBS-D患者中,口服膳食谷氨酰胺补充剂显著且安全地降低了所有主要IBS相关终点。
- 作者认为应开展大型随机临床试验以验证这些发现、评估生活质量获益并探索药理学机制。
研究设计与样本
- 随机、双盲、安慰剂对照、为期8周的试验。
- 纳入肠道感染后发生IBS-D且肠道通透性增高的成人患者,随机接受谷氨酰胺(5 g/次,每日三次)或安慰剂治疗8周。
- 54例谷氨酰胺组和52例安慰剂组受试者完成了8周研究。
- 主要终点为IBS严重程度评分系统(IBS-SS)评分降低≥50分。
- 次要终点包括IBS-SS原始评分、每日排便频率变化、粪便性状(Bristol粪便量表)和肠道通透性。
主要发现
- 主要终点在谷氨酰胺组43例(79.6%)中发生,安慰剂组3例(5.8%)中发生,差异达14倍。
- 8周时IBS-SS评分谷氨酰胺组301 vs 安慰剂组181,p<0.0001。
- 每日排便频率谷氨酰胺组5.4 vs 安慰剂组2.9±1.0,p<0.0001。
- Bristol粪便量表谷氨酰胺组6.5 vs 安慰剂组3.9,p<0.0001。
- 肠道通透性谷氨酰胺组0.11 vs 安慰剂组0.05,p<0.0001;肠道高通透性(尿乳果糖/甘露醇比值升高)在谷氨酰胺组恢复正常,而对照组未恢复。
关键数值与推荐
- 主要终点为IBS-SS评分降低≥50分。
- 谷氨酰胺给药方案为5 g/次,每日三次,持续8周。
- 肠道高通透性定义为尿乳果糖/甘露醇比值升高。
临床怎么用
- 原文未据此给出推荐。
- 作者结论认为在肠道感染后出现肠道高通透性的IBS-D患者中,口服膳食谷氨酰胺补充剂可显著且安全地降低所有主要IBS相关终点。
- 作者建议应开展大型随机临床试验以验证这些发现、评估生活质量获益并探索药理学机制。
局限性
- 作者在结论中提出应开展大型随机临床试验以验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection. METHODS: Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability. RESULTS: Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8%) in the placebo group (a 14-fold difference). Glutamine also reduced all secondary endpoint means: IBS-SS score at 8 weeks (301 vs 181, p<0.0001), daily bowel movement frequency (5.4 vs 2.9±1.0, p<0.0001), Bristol Stool Scale (6.5 vs 3.9, p<0.0001) and intestinal permeability (0.11 vs 0.05; p<0.0001). 'Intestinal hyperpermeability' (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group. Adverse events and rates of study-drug discontinuation were low and similar in the two groups. No serious adverse events were observed. CONCLUSIONS: In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. Large randomised clinical trials (RCTs) should now be done to validate these findings, assess quality of life benefits and explore pharmacological mechanisms. TRIAL REGISTRATION NUMBER: NCT01414244; Results.
引用
- Zhou Q, Verne ML, Fields JZ, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2018. PMID: 30108163. doi:10.1136/gutjnl-2017-315136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。